All In Biotech

Drug Trial Radar · NCT06670352

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

A Randomized, Double-blind, and Placebo-controlled Parallel Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients With Primary IgAN

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Oct 12, 2024

Primary completion

Dec 20, 2025

Study completion May 15, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Conditions

  • IgA Nephropathy (IgAN)

Interventions

  • PlaceboDrug

    QD or BID, 24-weeks fixed dose.

  • HSK39297 50mgBIDDrug

    24-weeks fixed dose.

  • HSK39297 100mgBIDDrug

    24-weeks fixed dose.

  • HSK39297 200mgQDDrug

    24-weeks fixed dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of 24-hour urine protein to creatinine (24h-UPCR) compared to baseline after 12 weeks of treatmentTime frame: From week 1 to week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.